Study confirms HPV genotypes responsible for majority of cervical cancers worldwide

October 17, 2010

Eight human papillomavirus (HPV) types (16, 18, 45, 33, 31, 52, 58, and 35) are responsible for over 90% of all cervical cancer cases worldwide, and should be the target of the next generation vaccines, according to the largest study of HPV genotypes to date, published Online First in The Lancet Oncology. HPV 16, 18, and 45 are the most common types and occur at a much younger age than other high-risk HPV genotypes. As such, these three HPV types should be the focus of future type-specific HPV screening.

Cervical cancer is the second most common cancer among women worldwide, and is predicted to result in nearly 328 000 deaths in 2010. The disease is caused by high-risk types of HPV. More than 118 different types of HPV have been identified, about 40 of these infect the genital tract, and 12 are known to be cancer causing. To effectively vaccinate against major cancer causing HPV types reliable information on the worldwide contribution of specific types of HPV to invasive cervical cancers is needed, particularly in developing countries where 80% of cases occur.

In this study, an international team led by Silvia de Sanjosé from the Catalan Institute of Oncology in Barcelona, Spain, investigated the role of different HPV types to the global incidence of invasive cervical cancer.

Samples from 10 575 cases of invasive cervical cancer diagnosed between 1949 and 2009 were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. PCR and DNA testing were used to identify the HPV genotype present in these tissue samples.

Over the 60 year study period, the eight most common HPV types identified were (in descending order of frequency) 16, 18, 45, 33, 31, 52, 58, and 35. Together they accounted for 91% of all cases of cervical cancer.

HPV 16, 18, and 45 were found in 75% of the most common type of cervical cancer (squamous cell) and 94% of adenocarcinomas (the second most common form).

Across five continents and despite a wide variety of screening programmes, women infected with HPV types 16, 18, and 45 were diagnosed with cervical cancers an average of 4 years earlier than women with other high-risk HPV types.

Current vaccines prevent infection by HPV types 16 and 18, and through cross protection partially HPV 31 and 45...The authors say: "Our findings of the early presentation of cases of invasive cervical cancer that were positive for HPV 45 suggest that this genotype should be considered in type-specific screening protocols and that women who are positive should be offered closer surveillance."

The researchers also identified rare HPV types (26, 30, 61, 67, 69, 82, and 91) in tumours as single infections, confirming their contribution to cervical cancer cases worldwide as small (about 1%).

They conclude: "This international effort...reinforces the rationale for prevention of cervical cancer through use of existing vaccines. Our results show which HPV types should be given priority when the cross-protective effects of current vaccines are assessed, and are useful for the formulation of recommendations about the use of second-generation polyvalent HPV vaccines."

In a Comment, Cosette Wheeler from the University of New Mexico Health Sciences Center, USA, says that although the findings largely confirm results of previous smaller studies: "the international effort must be recognised as a Herculean effort that might be the benchmark for all time. The combined data clearly support future directions for cervical screening and type-specific triage, establish the potential worldwide impact of current HPV vaccines, and set priorities for next-generation vaccines."

She adds: "Future HPV genomics and biomarker research...will be important to elucidate the molecular basis of increased carcinogenicity suggested by the HPV-genotype rank order reported in this study of worldwide invasive cervical cancer."
-end-
In addition, The Lancet group is holding a conference on "HPV and Cancer: Latest professional practice and future clinical management" on Nov 12-13, 2010 in Amsterdam, The Netherlands.

To register, please visit http://www.thelancetconferences.com/hpv-and-cancer/index.html. For a free media registration place, please email your press credentials to: emma.grainger@lancet.com

Dr Silvia de Sanjosé, Catalan Institute of Oncology, Barcelona, Spain. T) +34 649 073 782 E) s.sanjose@iconcologia.net

Dr Cosette Wheeler, University of New Mexico Health Sciences Center, Albuquerque, USA. T) +1 (505) 269 5817 or +1 (505) 867 3856 or +1 (505)272 5785 E) Cwheeler@salud.unm.edu

For full Article and Comment, see: http://press.thelancet.com/tlohpvtypes.pdf

NOTE: THE ABOVE LINK IS FOR JOURNALISTS ONLY; IF YOU WISH TO PROVIDE A LINK TO THE FREE ABSTRACT OF THIS PAPER FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70230-8/abstract

Lancet

Related Cervical Cancer Articles from Brightsurf:

HPV strains may impact cervical cancer prognosis
An analysis of cervical cancers in Ugandan women has uncovered significant genomic differences between tumours caused by different strains of human papillomavirus (HPV), signifying HPV type may impact cervical cancer characteristics and prognosis.

American Cancer Society updates guideline for cervical cancer screening
An updated cervical cancer screening guideline from the American Cancer Society reflects the rapidly changing landscape of cervical cancer prevention in the United States, calling for less and more simplified screening.

Disasters can affect cervical cancer screening for years
Screening is important for the early detection of cervical cancer, but rates were significantly affected, in some areas for years, following a devastating earthquake and tsunami in Japan.

Cervical cancer elimination possible within two decades in the US
At current levels of screening and HPV vaccination, cervical cancer incidence in the US is projected to fall below the threshold of elimination by 2038-2046.

Cervical cancer screening saves lives
Three-year interval in screening for cervical cancer is as effective as annual checkups, study finds.

Cervical cancer could be eliminated within a century
Cervical cancer could be eliminated worldwide as a public health issue within the next century.

25 years of learning to combat cervical cancer
A recent paper from the lab of Professor Sudhir Krishna at the National Centre for Biological Sciences, Bangalore, reviews the progress made in cervical cancer research over the past 25 years.

Cervical cancer screening numbers drop off in women 45-65
Virtually all cervical cancers are caused by HPV, and much of the attention in recent years has focused on preventing infections in younger women through HPV vaccination.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cost-effectiveness analysis of 12 cervical cancer screenings
This cost-effectiveness analysis incorporates women's preferences and estimates quality of life and economic outcomes for 12 cervical cancer screening strategies.

Read More: Cervical Cancer News and Cervical Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.